Welcome to the Virtual Press Room for the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 2022 (WCO-IOF-ESCEO)

A resource to provide you with information and tools to support your osteoporosis reporting during the WCO-IOF-ESCEO congress, 24-26 March 2022.

The referenced media source is missing and needs to be re-embedded.

This specialist press room will provide you with core information on topics within osteoporosis, as well as facts and figures, tools and resources. You’ll also find multimedia infographics, press materials and interviews with prominent healthcare professionals from across the sector until 4^th April 2022.

We appreciate that you may have additional questions or want to shape your story further; as such, if you would like an interview with one of the healthcare professionals featured within the Virtual Press Room resources or would like to speak to a senior UCB spokesperson, you can request this at any time via adriaan.snauwaert@ucb.com.

About WCO-IOF-ESCEO 2022

The annual WCO-IOF-ESCEO congress brings together the world’s best in the field of musculoskeletal health and disease. The congress aims to move the field forward by providing new insights into bone metabolism and pathology, while offering new strategies and options in prevention, diagnosis and treatment.

This year the meeting will be held virtually between 24^th and 26^th March, but with the same exciting scientific programme developed by the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) and the Scientific Advisory Board of European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). The virtual sessions will enable participants to interact with others in real time and the pre-recorded material will be available for registrants for 3 months from the opening of the Congress.

Core information assets for your use

_{WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY® (romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction}

Read the full press release

^{New UCB data analysis adds to demonstrated efficacy of romosozumab to reduce the risk of fractures}

Read the full press release

^{Fragility Fractures in Focus}

^{The cost of osteoporosis across Europe}

Find out more

^{Osteoporosis Factsheet}

Find out more

Osteoporosis and fragility fractures

Osteoporosis, meaning “porous bone”, is a condition in which the quality and density of bone are reduced, making bones weak, fragile, and more at risk of breaking. Sometimes bones can be so fragile that even a bump or fall from standing height can lead to a broken bone (commonly called a fragility fracture).¹

Globally, a fragility fracture caused by osteoporosis occurs every 3 seconds, which equates to approximately 9 million every year.² In fact, worldwide, it is estimated that one in three women over the age of 50 will suffer a fragility fracture due to osteoporosis in their lifetime.²

As the world’s older population continues to grow, the number of fragility fractures is predicted to rise. Despite this, around 80% of “high-risk” individuals are neither identified nor treated for osteoporosis, even though the risk of suffering from a subsequent fracture within one year is increased 5-fold.^3,4

For more information, please view the Virtual Press Room’s osteoporosis factsheet.

At UCB, we are committed to enabling people living with severe diseases, their caregivers, and their families to live their best lives. To achieve this, we focus on the discovery and development of innovative medicines and solutions.

References

Overview